INTRODUCTION
The successful treatment of early myelofibrosis with recombinant interferon-a (rIFNa) has been reported by us and others; however, in those studies, the effect of driver mutations (ie, JAK2, CALR, and MPL mutations) and epigenetic or other mutations at diagnosis were not considered, and systematic bone marrow examinations were not performed. [1] [2] [3] [4] The molecular abnormalities in patients with myelofibrosis have recently been emphasized, and their incorporation into a new prognostic scoring system has been recommended as an improvement over the Dynamic International Prognostic Scoring System (DIPSS) or its variations. 5, 6 Here, we report on 30 patients, expanded from our initial cohort of 17, whose molecular abnormalities at baseline were correlated with hematologic and bone marrow response and survival after treatment with rIFNa.
Molecular abnormalities at diagnosis have been investigated in patients with both primary myelofibrosis (PMF) and secondary myelofibrosis (SMF). [5] [6] [7] [8] [9] [10] [11] No correlation between initial mutation status and response to treatment with ruxolitinib or overall survival (OS) was reported in patients with PMF or SMF. 7, 8 Patel et al reported that patients with 3 or more mutations had a lower OS and a shorter time to treatment discontinuation. 7 Although individual driver mutations had no correlation with response to treatment with ruxolitinib, spleen response (50% reduction in palpable splenomegaly) was inversely correlated with the number of mutations derived from a standard myeloid panel. Furthermore, patients with 1 or more mutations in ASXL1, EZH2, and IDH1/2 were significantly less likely to have a spleen response than those without such mutations. 7 Recently, several mutations have been identified that categorize patients as "high molecular risk" (HMR). 5 Specifically, these mutations include ASXL1, EZH2, SRSF2, and IDH1/2, which have been associated with both shorter OS and an increased risk of transformation to acute leukemia. 5 Furthermore, 2 or more mutations were associated with a worse prognosis than 1 or none. 9 Although these secondary epigenetic abnormalities have been generally accepted as associated with an adverse prognosis, their association with response to treatment with rIFNa has never been examined.
Patients who have PMF with CALR mutations reportedly have better OS than those with JAK2, MPL, or no driver mutations, whereas triple-negative patients have a significantly shorter survival. 6, 9, 10 In multivariate analysis that included both driver and epigenetic abnormalities, only CALR and ASXL1 mutations remained prognostically significant; CALR had a favorable impact on prognosis, and ASXL1 had a negative impact. 10 Therefore, the authors suggested that individuals with CALR-negative, ASXL1-positive or triple-negative PMF should be considered HMR patients. However, these patients were not treated uniformly.
We now report results from our single-center study of 30 patients with either primary or secondary MF and correlate their initial molecular and epigenetic profiles with their clinical and hematologic responses to treatment with rIFNa.
MATERIALS AND METHODS
The study was approved by our Institutional Review Board and performed according to the Declaration of Helsinki. Patients were diagnosed using World Health Organization (WHO) criteria for PMF and International Working Group for Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria for postpolycythemia vera (post-PV)and post-essential thrombocythemia (post-ET) MF. 12, 13 Evaluation included medical history and physical examination; complete blood and differential counts; routine serum chemistries; liver, renal, and thyroid function tests; bone marrow biopsy; BCR-ABL1 determination; cytogenetic evaluation; epigenetic testing; and JAK2, CALR, and MPL analyses. Spleen size was measured in centimeters below the left costal margin (BLCM) in the midclavicular line. Prognosis was assessed using IWG-MRT DIPSS scores. 14 We used DIPSS instead of the more recent DIPSS-Plus 15 because, by definition, none of our patients with early phase MF required any transfusions at study onset. Treatment response was assessed using the consensus criteria of the IWG-MRT and European LeukemiaNet (ELN). 16 Response classifications included complete remission (CR), partial remission (PR), clinical improvement (CI), stable disease (SD), and progressive disease (PD).
Bone marrow specimens were stained with hematoxylin and eosin, Giemsa, and with silver and trichrome for reticulin and collagen. Fibrosis was graded using the European Consensus System. 17 Criteria for inclusion in this study required a prognostic score of either low or intermediate-1 and residual hematopoietic foci occupying 15% of the bone marrow biopsy. Bone marrow aspirates were submitted for cytogenetic analysis when sufficient material could be obtained.
JAK2 and CALR mutations were detected and/or quantified by pyrosequencing and MiSeq analysis, respectively, according to previously described methods. [18] [19] [20] Patients who were JAK2-negative were retrospectively evaluated for CALR and MPL mutations.
Genomic DNA was extracted from frozen mononuclear cells, which were isolated from peripheral blood collected at the time of diagnosis. Next-generation sequencing was performed using a custom, 45-gene, myeloid malignancy-targeted, amplicon-enrichment panel (RainDance Technologies, Billerica, Mass) that included 45 genes recurrently mutated in myeloid malignancies (ABL1, ASXL1, BCOR, BRAF, CALR, CBL, CEBPA, DNMT3A, ETV6, EZH2, FAM5C, FLT3, GATA1, GATA2, HNRNPK, IDH1, IDH2, IKZF1, JAK1, JAK2, KDM6A, KIT, KRAS, MPL, NFE2, NOTCH1, NPM1, NRAS, PHF6, PTPN11, RAD21, RUNX1, SETBP1, SF3B1, SH2B3, SMC1A, SMC3, SRSF2, STAG2, SUZ12, TET2, TP53, U2AF1, WT1, and ZRSR2). Amplicons were sequenced on an Illumina MiSeq (v3 chemistry; Illumina, San Diego, Calif) using 260-basepair (bp), paired-end reads followed by alignment to the human reference genome (hs37d5) using BWA MEM.
Mutations were identified using VarDict, 22 excluding primer regions, and were annotated using SnpEff 4.1. 23 Common SNPs likely to be nonsomatic with minor allele frequency greater than 0.25% were excluded from subsequent analysis with the exception of variants identified at least twice in the Catalog of Somatic Mutations in Cancer (v68). 24 The cutoff point for positive mutation status for all mutations was 5%.
Descriptive statistics (including means, standard deviations, medians, ranges, frequencies, and percentages) were calculated to characterize the study cohort. The relation between various definitions of mutation status and 1) response (CR/PR/CI/SD vs relapse/PD/death; CR/PR/ CI vs SD/PD/relapse/death) and 2) prognostic factors of interest were assessed using the Fisher exact test. KaplanMeier survival analysis was performed to assess OS and progression-free survival (PFS), and the log-rank test was used to compare PFS between categories of spleen size (<4 cm vs. 4 cm). All P values are 2-sided, and statistical significance was evaluated at the a 5 .05 level. All analyses were performed in SPSS version 24.0 (SPSS Inc., Chicago, Ill) and Stata version 14.0 (StataCorp, College Station, Tex).
Either rIFNa-2b or pegylated IFNa-2a (peg-IFNa2a) was used, depending on insurance coverage and patient desire. Eighteen patients initially received rIFNa2b (from 500,000 to 1 million units subcutaneously 3 times weekly, gradually increasing the dose to 2 to 3 million units 3 times weekly, as tolerated and to reduce spleen size, which was used as a clinical indicator of response). Seven patients received 45 or 90 lg peg-IFNa-2a weekly. Five patients began treatment with rIFNa-2b, but their treatment was changed to peg-IFNa-2a (at the aforementioned doses) after a median of 2 years because of their preference and insurance availability. Contraindications to initiating rIFNa included severe depression, neuropathy, active thyroid dysfunction, current or past history of autoimmune disease, current or past history of inflammation-mediated comorbidities, and significant hepatic, renal, or cardiac abnormalities. Adjustment and final selection of a maintenance dose was based on clinical and bone marrow response, tolerability, and toxicity, which were assessed using the Common Terminology Criteria, version 4.0 (National Cancer Institute, National Institutes of Health, Department of Health and Human Services, May 29, 2009 ). 12 or IWG-MRT criteria for SMF, 13 66 were excluded because of marked bone marrow fibrosis and <15% hematopoietic foci or unwillingness to be treated with IFN in the early phase of their disease. The remaining 30 patients (31%) met our study inclusion criteria. There were 16 women and 14 men, and their median age at the time of diagnosis was 58 years (range, 34-72 years) ( Table  1) . Twenty-one patients (70%) met the WHO criteria for PMF, 7 (23%) met the criteria for post-PV MF, and 2 (7%) met the criteria for post-ET MF. 12, 13 Twenty-two patients were positive for the JAK2 V617F , 6 were positive for CALR, and 2 were positive for MPL. Of the CALRpositive patients, 5 had the 52-bp (type 1) deletion, and 1 had a 19-bp deletion; and, of the MPL-positive patients, 1 had a W515K variant, and the other had a W515L variant. All 7 patients in the post-PV MF group were positive for the JAK2 V617F mutation. Of the post-ET MF group, 1 patient was positive for JAK2 V617F , and 1 was positive for CALR. Of the patients with PMF, 14 were positive for JAK2 V617F , 5 were positive for CALR, and 2 were positive for MPL.
RESULTS

Of 96 patients who met 2008 WHO criteria for PMF
Twenty-two patients were classified as low-risk, and 8 were classified as intermediate-1 risk. Median baseline leukocyte, hematocrit, hemoglobin, and platelet values were 9 3 1000/lL, 38.4%, 12.9 g/dL, and 345,500/lL, respectively; the median values at last follow-up were 7 3 1000/lL, 36.4%, 11.8 g/dL, and 279,000 /lL. The median disease duration before rIFNa treatment was 1.9 years from PMF or SMF diagnosis, and the median duration of treatment to date has been 5.6 years.
Of 30 patients, 2 (7%) achieved CR, 9 (30%) achieved PR, 4 (13%) had CI, and 7 (23%) had SD (Tables 2 and 3 ). Four patients (13%) had PD, and 4 (13%) died, including 3 deaths from PD, although 1 patient was not compliant with respect to rIFNa use, and 1 died 6 weeks after bone marrow transplantation. Nine of 22 low-risk patients, but only 2 of 8 intermediate-1-risk patients, achieved CR or PR.
Baseline and follow-up spleen measurements were available for all patients. Of 30 patients, 8 (27%) had no splenomegaly at onset of rIFNa therapy, and 6 of those 8 patients (75%) remained without splenomegaly during their treatment (median, 5.5 years). Six of 10 patients (60%) with "slight" splenomegaly (spleen size, <4 cm BLCM) achieved nonpalpable spleens after a median of 10.8 years of therapy. Both patients with moderate splenomegaly (spleen size, 4-9 cm BLCM) had an increase in spleen size at a median of 4.6 years. Of the 10 patients with marked splenomegaly (spleen size, >9 cm BLCM), 4 (40%) responded with at least a 50% reduction in spleen size (median duration of treatment, 5.7 years). The remaining 6 patients (60%) had either a slight decrease or stable spleen size. Overall, the 18 patients who had a spleen size <4 cm (60%) had a better response to treatment than those who had significant splenomegaly; 2 achieved CR, 9 achieved PR, 1 had CI, 4 remained stable, 1 had PD, and 1 died. Of the nonresponders, 2 patients had HMR mutations, including 1 patient who had 3 mutations. Conversely, of the 12 patients who had significant or moderate baseline splenomegaly, including the 2 with HMR mutations and 1 with 4 mutations, 3 achieved CI, 3 remained stable, 3 progressed, and 3 died. In summary, a large spleen before the start of therapy was associated with worse PFS (P 5 0.02; log-rank test); however, patients with small spleens and HMR mutations did not respond to rIFNa.
Toxicity was generally mild, grade 1 or 2, doserelated, and subsided or diminished upon dose reduction (Table 4) . These included mild depression, dry skin, cough, myalgia, fatigue, and asthenia. Overall, the myelosuppressive effects of rIFNa were mild. Seventeen patients developed increasing anemia (13, grade 1; 4, grade 2), and 2 had grade 3-4 thrombocytopenia. In these patients, the doses of IFN were temporarily reduced or interrupted until cytopenias resolved. One patient developed hyperthyroidism, and treatment was discontinued.
Follow-up bone marrow biopsies were possible in 25 of 30 patients (83%). Reduction in cellularity occurred in 12 patients, an increase was observed in 3, and no change was observed in 8 (baseline cellularity was unreported for 2). Five patients had a reduction in reticulin fibrosis, 10 remained stable, and 9 patients had an increase (baseline fibrosis score was unreported for 1). Unequivocal improvement in bone marrow morphology occurred in 12 of 30 patients (40%). However, even in the 2 patients categorized with CR according to ELN criteria, subtle abnormalities in megakaryocyte nuclear structure persisted. Of 11 patients who had reductions in splenomegaly and also evaluable bone marrow biopsies, 8 had a reduction in cellularity (73%), 2 had no change, and 1 had increased cellularity. In general, therefore, the majority of patients with a reduction in spleen size had an improvement in bone marrow morphology.
Of all 30 patients, baseline bone marrow cytogenetic analyses were available in 22, and sequential cytogenetic analyses were available in 15. Of 13 patients who had normal cytogenetics at baseline, 1 developed 213q, 1 developed trisomy 9, and the rest remained normal. Two patients had baseline cytogenetic abnormalities that did not change over the course of treatment: 1 had trisomy 9, and 1 had 213q. Previous reports indicated that these cytogenetic abnormalities are favorable in this disease. [25] [26] [27] No statistically significant differences occurred between the type of driver mutation and response to treatment (IWG-MRT; Fisher exact test; P 5 .65). There was no significant correlation between driver mutation and DIPSS score at baseline (data not shown).
Of the 30 patients, 22 (73%) were JAK2
V617F
-positive. The mean JAK2 mutant allele burden at baseline for the low-risk and intermediate-1-risk groups was 47.6% (range, 4.9%-93%) and 48.1% (range, 10.1%-95.3%), respectively. The range of baseline mutant allele burden was also similar in both groups. Of 18 follow-up specimens, 5 had both a median mutant allele burden decrease of 23% (range, 9%-58%) and a decrease in bone marrow cellularity after a median treatment duration of 7 years (range, 1.5-12 years). There was no consistent or statistical correlation between a decrease in JAK2 V617F allele burden, clinical response, bone marrow fibrosis, or spleen size (data not shown).
Additional mutational analyses were possible in 25 of 30 patients (83%) ( Table 3 ). Of 12 patients who had a CI or better, none had a known HMR mutation. Of 6 patients who remained stable, 1 had an HMR mutation (ASXL1). Of 8 patients who progressed or died, 7 were tested with the next-generation sequencing panel, and 3 had HMR mutations (ASXL1 and SRSF2). Patients with known HMR mutations had worse responses than those without; of 4 patients with such mutations, 1 progressed, and 2 died. The other patient remained stable. All 4 of these patients had PMF. Patients who had 3 or more mutations fared worse than those with fewer. Of 5 patients who had 3 or more mutations, 2 progressed, and 2 died; all 4 patients had PMF. The other patient, who had post-PV MF, attained PR. In addition, patients without the ASXL1 mutation seemed to do better than patients with it, although sample size precluded a definitive statement (P 5 .19). In this selected group of patients, at 5 years, the OS rate was 91.5%, and the PFS rate was 88% (Fig. 1) .
DISCUSSION
This is the first study correlating initial driver, epigenetic and other mutations with documented clinical and bone marrow responses to rIFNa therapy. Our current results suggest that therapeutic intervention with rIFNa before the development of clinically significant adverse features, such as marked splenomegaly, anemia, and florid myelofibrosis and osteosclerosis is beneficial in patients who have early stage disease. The majority of these patients improved or remained stable (73%), regardless of whether their initial DIPSS score was low or intermediate-1, suggesting that treatment with low-dose rIFNa should be initiated before patients develop the cascading events that precede features of irreversible disease. In this selected group of patients, OS and PFS were impressive but, of course, inconclusive. Initial driver mutations did not correlate with response to treatment, consistent with the response of ruxolitinib-treated patients with MF; no correlation between the type of genetic mutation and spleen response or survival was noted in such patients; however, there was an inverse correlation between the number of initial mutations and response.
7 CALR-positive patients did not have superior response or survival, differing from the findings of others who observed a better OS and lower risk of thrombosis in CALR-positive patients compared with JAK2-positive, MPL-positive, or triple-negative patients. 6, 9, 10 Those studies included neither a full myeloid mutational evaluation nor treatment specification. This is important, because the lack of correlation between mutational status and response to treatment may be therapy-specific and not a generality, possibly accounting for the various results to date correlating driver, epigenetic Thus, although baseline driver mutation status was not useful prognostically, a molecular profile at diagnosis should be performed to identify HMR abnormalities, because these negatively affect response to treatment, including rIFNa. Three of 4 patients who had HMR abnormalities (ASXL1 or SRSF2) had a poor response, all with PMF, compared with only 4 poor responders in 20 patients with low molecular risk.
The use of low-dose rIFNa in "early" PMF, post-ET MF, and post-PV MF, as defined above, resulted in bone marrow reversion, regression of splenomegaly, and disease stabilization with tolerable toxicity in 73% of patients.
Reduction in splenomegaly appears to be predictive of improvement in bone marrow morphology and may be used as a guide for continuing therapy in the absence of HMR. We emphasize that long-term treatment must be anticipated when using low-dose rIFNa. The median therapy duration was 5.6 years and is still ongoing for approximately 50% of the patients. The finding that subtle but definite structural megakaryocytic abnormalities persist in patients who are in CR suggests that "biologic remission" but not "cure" has been achieved, analogous to the responses in chronic myeloid leukemia and PV. 28 Thus, it is perhaps more appropriate to consider these changes "complete response," as opposed to "complete remission."
The OS of patients with PMF who received treatment with rIFNa was favorable compared with that of patients who received a variety of therapies. 29 In a group of 208 low-risk and intermediate-1-risk patients, median survival was 10.6 years, whereas median survival for our patients was not yet reached, and the OS rate at 10.6 years is 72.7%. This suggests that early treatment with rIFNa is not harmful and may offer survival benefit, despite the usual caveats of analyzing survival in a small cohort with relatively few deaths.
Although it has been argued that "observation only" is most appropriate for low-risk patients because of their long survival, 30 such a recommendation does not account for interval symptoms and morbidity during the course of the disease. We acknowledge that, in following our treatment recommendations, a measurable cohort of patients may receive rIFNa prematurely. Conversely, a significant number of patients who will require the drug may not. Unhappily, this is true for many other forms of chemotherapy. The symptom burden in patients with MF has long been emphasized and must be considered for all patients. 31 Unquestionably, the future requires much improved risk-adaptive therapy, hopefully on a molecular basis. Although our results are encouraging, patient selection and sample size play a critical role, requiring confirmation in a larger and preferably randomized trial. However, the importance and value of single-arm studies in orphan diseases has recently been analyzed and discussed. 32, 33 Nevertheless, until there are further systematic evaluations of IFN in early myelofibrosis, it remains an experimental therapy. 
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